Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[Q]: Today’s fit-focused travelers want to pair exercise with escapades and fitness with fun, whether it’s yoga among the sea turtles, bootcamp on the beach or a zumba cruise. “Fitness retreat used to mean go away and lose weight,” said Melisse Gelula, co-founder of the wellness media company Well+Good. “Now it’s just working fitness into a schedule that might also include lavish dinners, beach time, cocktail hours, nights out dancing.”  Wellness tourism, which includes travel paired with activities such as yoga retreats, fitness centers, boot camps, cycling, gyms and other activities, is about a $500 billion global market, according to The Global Wellness Tourism Economy report of 2013. The report said wellness tourism represents 14 percent of total global tourism revenues overall and is projected to rise to 16 percent by 2017. In January, Royal Caribbean Cruises Ltd will launch its first ever Zumba Cruise, offering all-day classes in the popular Latin American dance-based aerobic program during a  cruise that will leave from Fort Lauderdale in Florida and make stops in Jamaica and Haiti. Daily classes will be led by 130 zumba instructors. “Our focus is more fun,” said Allison Robins of the global lifestyle brand Zumba Fitness, which is working with the cruise line. “You’ll never see us talking about weight loss, although that just happens.”  Maria Walker, founder of Getaway Fitness in Florida which offers workout vacations in Florida and California, refers to the growing industry as fitness adventure. “When I started, there were spa resorts and fat camps but not much in  the middle,” said Walker, whose clients are mostly  people in their 30s, 40s and 50s. Now activities range from boot camp and rock climbing to kayaking, and discussions focus more on exercise and nutrition than weight loss. YogaWorks, the national chain of yoga studios, offers 10 to 15 retreats a year and plans to scale up offerings in 2016. “It’s definitely a growing part of the business,” said spokesperson Kim Allardyce, adding it is not just about perfecting one’s yoga postures. Although the emphasis is on yoga, depending on where the tour is, local sites are also included. In Costa Rica vacationers might help release sea turtles and in Italy go on wine-tasting excursions. The goal, she said, is to marry fitness with an experience specific to the location.
[A]: Fitness vacations favor fun, adventure over weight loss.


[Q]: But that was before being told by doctors in August that he had a degenerative spinal condition that could have left him paralyzed. Hurley returned to work full time Wednesday, less than two weeks after having surgery to replace two disks in his neck with artificial ones. He expects to make a full recovery, but says as health scares go, this was terrifying. “I started worrying and having a lot of anxiety about my health and my ability to get back to being myself,” he said. “You start playing worst-case scenarios in your head.” Hurley said doctors told him the condition was part hereditary and part a result of years of the wear and tear associated with being a life-long athlete. He said he was hoping to deal with the discomfort and tingling he was feeling through physical therapy or maybe an injection, but doctors quickly told him that he needed immediate surgery and that any hard fall or bump could leave him paralyzed. He had the surgery on Sept. 6, with the doctor using an incision in his throat to get to his spine. He said he was told that for experts, it’s a relatively routine procedure. The 46-year-old coach said he felt better immediately, but still has some restrictions for the next month, such as being prohibited from flying or lifting anything heavier than 10 pounds. Hurley, known for his animated coaching style, said he’s kept recruits informed and is very confident the situation won’t have any long-term effects on his ability to do his job the way he always has done it. But, he said the first major health issue has changed his perspective on life. “How important my faith is to me was reinforced; how important my family is to me was reinforced,” he said. “And just how important I am to my players, to not just succeed and excel in their careers. My true sense and purpose as a coach came into much clearer focus for me.” His players gave him a warm welcome back on Wednesday. He said that meant a lot to him, but didn’t make him go any easier on them. “Any of like that feeling sorry for me or good will toward the coach returning from injury went out the door when I got on guys for their lack of defensive prowess,” he said. “Yeah, all that love is gone.” UConn opens its season Nov. 8 against Sacred Heart.
[A]: UConn men’s coach Hurley back at work after spinal surgery.


[Q]: The European Medicine Agency (EMA) also backed a new drug from Dainippon Sumitomo Pharma called Latuda, for the treatment of schizophrenia, and Bemfola, a new biosimilar medicine for the treatment of infertility. But the regulator decided against recommending Teva’s new multiple sclerosis (MS) pill Nerventra, or laquinimod, which the Israeli firm is developing with Swedish partner Active Biotech, and recommended rejecting an application from Swiss drugmaker Novartis to market its heart failure drug serelaxin. Recommendations for marketing approval by the EMA’s Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months. The prospects for laquinimod were already viewed by analysts as uncertain, since the drug missed its main goal in a late-stage trial in 2011 and U.S. regulators have asked for another Phase III study before considering it. Analysts at Jefferies in London said the rejection of Teva’s MS drug was as they had expected and was driven by three major concerns - about the possible link to risk of cancers and pregnancy dangers, and its modest effect on relapse rates which suggested an unfavorable risk-benefit balance for the drug. On Bayer’s Adempas, the EMA said the key benefits of the drug were “its ability to provide significant improvement in exercise capacity and pulmonary haemodynamics in two specific conditions known as chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension.”  Adempas, which belongs to a class of drugs known as soluble guanylate cyclase stimulators that help arteries relax to increase blood flow and decrease blood pressure, got backing from drugs regulators in United States in October last year, and in Japan earlier this month. The EMA also issued negative opinions for two so-called orphan medicines - Masiviera from France’s AB Science, intended for certain types of advanced pancreatic cancer, and Translarna, from PTC Therapeutics, designed to treat Duchenne muscular dystrophy. GSK’s once-weekly diabetes drug albiglutide won the EMA’s recommendation and will be sold under the brand name Eperzan. It belongs to the same class of injectable GLP-1 drugs as Victoza, from Novo Nordisk, as well as Byetta and Bydureon, from Bristol-Myers Squibb and AstraZeneca. Last year regulators in the United States pushed back an approval decision on the drug until April 15.
[A]:
EU regulator backs Bayer, GSK drugs, knocks back Novartis, Teva.